4//SEC Filing
MCGRATH JOHN 4
Accession 0001209191-18-020971
CIK 0001604464other
Filed
Mar 19, 8:00 PM ET
Accepted
Mar 20, 6:30 PM ET
Size
7.1 KB
Accession
0001209191-18-020971
Insider Transaction Report
Form 4
MCGRATH JOHN
Chief Financial Officer
Transactions
- Sale
Common Stock
2018-03-19$41.99/sh−3,000$125,970→ 91,762 total - Sale
Common Stock
2018-03-20$38.83/sh−3,000$116,490→ 88,762 total
Footnotes (3)
- [F1]Transaction pursuant to Rule 10b5-1 Plan adopted July 6, 2016.
- [F2]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $41.90 to $42.075. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- [F3]The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Documents
Issuer
Atara Biotherapeutics, Inc.
CIK 0001604464
Entity typeother
Related Parties
1- filerCIK 0001205442
Filing Metadata
- Form type
- 4
- Filed
- Mar 19, 8:00 PM ET
- Accepted
- Mar 20, 6:30 PM ET
- Size
- 7.1 KB